Home » Stocks » IMTX

Immatics N.V. (IMTX)

Stock Price: $10.43 USD 0.07 (0.68%)
Updated Mar 5, 2021 3:53 PM EST - Market closed
Market Cap 663.06M
Revenue (ttm) 18.45M
Net Income (ttm) -35.20M
Shares Out 17.97M
EPS (ttm) -27.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $10.43
Previous Close $10.36
Change ($) 0.07
Change (%) 0.68%
Day's Open 10.37
Day's Range 10.30 - 10.74
Day's Volume 242,175
52-Week Range 8.66 - 17.25

News

There are no news available yet.

About IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets... [Read more...]

Industry
Biotechnology
CEO
Dr. Harpreet Singh
Employees
230
Stock Exchange
NASDAQ
Ticker Symbol
IMTX
Full Company Profile

Financial Performance

In 2019, Immatics's revenue was $18.45 million, an increase of 389.36% compared to the previous year's $3.77 million. Losses were -$31.57 million, 0.40% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Immatics stock is "Strong Buy." The 12-month stock price forecast is 17.65, which is an increase of 69.22% from the latest price.

Price Target
$17.65
(69.22% upside)
Analyst Consensus: Strong Buy